Immunoblot of tumor bulk protein and in situ immunohistochemistry indicated that MIR31HG ASO therapy downregulated expression of GLI2, ABCG2, and SOX2 (Fig. 6G, H, Fig. S10B, C). The gene discussed is ABCG2; the disease is neoplasm.